Study examined healthcare costs between ibrutinib and acalabrutinib for treatment of CLL.
Home / Resource Library / A real-world study evaluating drug tolerability and health care resource use with acalabrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma